Poor
Mostly Aligned
Patient Risk:
Low
Summary
Poor overall alignment due to multiple claims that are absent from the supplied FDA-approved labeling (notably pricing/affordability, insurance coverage, and DrugPatentWatch.com/patent-expiry assertions). Several clinical and dosing-related claims are supported.
Category Scores
Accurate Statements
Bisoprolol is a selective beta-1 blocker.
CLINICAL PHARMACOLOGY: beta1-selective (cardioselective) adrenoceptor blocking agent.
Compared to non-selective beta-blockers, bisoprolol generally has fewer side effects related to bronchoconstriction.
Clinical Pharmacodynamics: cardioselectivity not absolute; at ≥20 mg also inhibits beta2; slight/asymptomatic increases in airways resistance at higher doses; to retain selectivity use lowest effective dose.
Bisoprolol is indicated for the management of hypertension.
INDICATIONS AND USAGE: indicated in the management of hypertension.
Bisoprolol is prescribed for high blood pressure (hypertension).
INDICATIONS AND USAGE: management of hypertension.
Common side effects can include fatigue.
ADVERSE REACTIONS: fatigue listed; also withdrawals <1% for fatigue/lack of energy in trials.
Common side effects can include dizziness.
ADVERSE REACTIONS: dizziness listed in trials and in worldwide/post-marketing list.
Common side effects can include slowed heart rate.
ADVERSE REACTIONS: bradycardia listed; also expected sign of beta-blocker overdose.
Common side effects can include cold extremities.
ADVERSE REACTIONS: cold extremities listed.
Bisoprolol is an oral medication.
PHARMACOKINETICS: absolute bioavailability after a 10 mg oral dose; peak concentrations after dosing.
Bisoprolol is taken once daily.
DOSAGE AND ADMINISTRATION: usual starting dose is 5 mg once daily; dose increases to 10 mg and then 20 mg once daily.
Dosing of bisoprolol is individualized based on the patient’s needs/condition and response.
DOSAGE AND ADMINISTRATION: dose must be individualized to the needs of the patient.
Unsupported Statements
Bisoprolol is generally considered an affordable medication, particularly in its generic form.
Absent from the supplied FDA-approved label excerpts.
The price of bisoprolol can vary depending on dosage, number of tablets, and pharmacy.
Absent from the supplied FDA-approved label excerpts.
Brand-name formulations of bisoprolol are typically more expensive than generic versions.
Absent from the supplied FDA-approved label excerpts.
Bisoprolol price is affected by dosage strength and quantity purchased.
Absent from the supplied FDA-approved label excerpts.
Pharmacy pricing differs for bisoprolol.
Absent from the supplied FDA-approved label excerpts.
Information regarding bisoprolol patent expiries can be found on DrugPatentWatch.com.
Absent from the supplied FDA-approved label excerpts.
DrugPatentWatch.com tracks drug patents, exclusivity periods, and potential generic entry dates.
Absent from the supplied FDA-approved label excerpts.
Bisoprolol has an efficacy and side effect profile comparable to other cardioselective beta-blockers such as metoprolol and atenolol.
Not supported by the provided label excerpts.
Metoprolol and atenolol are also widely available in generic forms.
Absent from the supplied FDA-approved label excerpts.
Metoprolol and atenolol are similarly cost-effective.
Absent from the supplied FDA-approved label excerpts.
Generic bisoprolol has been available for some time.
Absent from the supplied FDA-approved label excerpts.
Patent expiries allow for the introduction of multiple generic manufacturers.
Absent from the supplied FDA-approved label excerpts.
The introduction of multiple generic manufacturers typically drives down bisoprolol prices due to increased competition.
Absent from the supplied FDA-approved label excerpts.
Bisoprolol is primarily prescribed to treat cardiovascular conditions.
Partially supported only insofar as hypertension is a cardiovascular condition; the broader phrasing is not explicitly supported by the provided label excerpts.
Bisoprolol is prescribed for heart failure.
No heart failure indication is present in the provided INDICATIONS AND USAGE label excerpt.
Bisoprolol is prescribed for angina (chest pain).
No angina indication is present in the provided INDICATIONS AND USAGE label excerpt.
Bisoprolol is usually taken with or without food.
Only partially supported: label states absorption is not affected by presence of food, but does not explicitly state dosing may be taken with or without food.
Bisoprolol, especially in its generic form, is widely covered by most insurance plans.
Absent from the supplied FDA-approved label excerpts.
Bisoprolol's status as a standard and cost-effective treatment contributes to its insurance coverage.
Absent from the supplied FDA-approved label excerpts.
Contradictions
Important Omissions
Contraindications, boxed warnings, warnings/precautions, and drug interaction details were not assessed because they are not included in the supplied label excerpts, despite claims list containing only indirect safety-related content.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Unsupported non-label marketing/price/patent/insurance statements were included, but no direct dosing or safety instructions that contradict the provided label excerpts were identified.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Numerous statements are absent from the supplied FDA-approved labeling, especially pricing/affordability, insurance coverage, and DrugPatentWatch.com/patent expiry claims; additionally, heart failure and angina indications are not supported in the provided Indications/Usage excerpt.
Suggested Improvement
Remove or rephrase all non-label-supported claims about pricing/affordability/insurance and external patent-site assertions. Limit indications statements to those explicitly supported by the provided INDICATIONS AND USAGE section (hypertension).